Cargando…

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol

BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Namikawa, Tsutomu, Maeda, Hiromichi, Kitagawa, Hiroyuki, Oba, Koji, Tsuji, Akihito, Yoshikawa, Takaki, Kobayashi, Michiya, Hanazaki, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812232/
https://www.ncbi.nlm.nih.gov/pubmed/29439671
http://dx.doi.org/10.1186/s12885-018-4109-z
_version_ 1783300009392865280
author Namikawa, Tsutomu
Maeda, Hiromichi
Kitagawa, Hiroyuki
Oba, Koji
Tsuji, Akihito
Yoshikawa, Takaki
Kobayashi, Michiya
Hanazaki, Kazuhiro
author_facet Namikawa, Tsutomu
Maeda, Hiromichi
Kitagawa, Hiroyuki
Oba, Koji
Tsuji, Akihito
Yoshikawa, Takaki
Kobayashi, Michiya
Hanazaki, Kazuhiro
author_sort Namikawa, Tsutomu
collection PubMed
description BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of S-1 for one year. METHODS: This multicenter phase II study evaluate the efficacy and safety of adjuvant chemotherapy using S-1 plus oxaliplatin followed by S-1 for up to one year for curatively resected stage III gastric cancer in patients aged over 20 years. Treatment initially comprises oral fluoropyrimidine S-1 (80 mg/m(2)) administered twice daily for the first 2 weeks of a 3-week cycle. On day 1 of a second 3-week cycle, patients will receive 100 mg/m(2) of intravenous oxaliplatin followed by 80 mg/m(2) of S-1 (maximum 8 cycles). Then, the patients will receive 80 mg/m(2) of S-1 daily for 4 weeks, followed by 2 weeks of no chemotherapy. This 6-week cycle will be repeated during the first year after surgery. The primary endpoint is relapse-free survival for 3 years and secondary endpoints are safety, including the incidence of adverse events, and grading of neuropathy with each treatment cycle. The planned sample size of 75 patients is appropriate for this trial. The data will be analyzed on an intention-to-treat basis, assuming a two-sided test with a 5% level of significance. DISCUSSION: In contrast to previous trials, the current study involves administration of S-1 until one year after surgery in addition to prior S-1 plus oxaliplatin, and is the first study to evaluate the safety and efficacy of S-1 plus oxaliplatin followed by S-1 for up to one year in patients with curatively resected stage III gastric cancer. TRIAL REGISTRATION: This trial is registered in the University Hospital Medical Information Network’s Clinical Trials Registry (UMIN-CTR) registration number, R000029656  (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029656). Registered January 24, 2017.
format Online
Article
Text
id pubmed-5812232
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58122322018-02-15 Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol Namikawa, Tsutomu Maeda, Hiromichi Kitagawa, Hiroyuki Oba, Koji Tsuji, Akihito Yoshikawa, Takaki Kobayashi, Michiya Hanazaki, Kazuhiro BMC Cancer Study Protocol BACKGROUND: Recent studies demonstrated the efficacy of S-1-based adjuvant chemotherapy administered for six months after curative surgery for stage III gastric cancer; however, it is unproven whether this type of combination chemotherapy is more effective than the standard adjuvant chemotherapy of S-1 for one year. METHODS: This multicenter phase II study evaluate the efficacy and safety of adjuvant chemotherapy using S-1 plus oxaliplatin followed by S-1 for up to one year for curatively resected stage III gastric cancer in patients aged over 20 years. Treatment initially comprises oral fluoropyrimidine S-1 (80 mg/m(2)) administered twice daily for the first 2 weeks of a 3-week cycle. On day 1 of a second 3-week cycle, patients will receive 100 mg/m(2) of intravenous oxaliplatin followed by 80 mg/m(2) of S-1 (maximum 8 cycles). Then, the patients will receive 80 mg/m(2) of S-1 daily for 4 weeks, followed by 2 weeks of no chemotherapy. This 6-week cycle will be repeated during the first year after surgery. The primary endpoint is relapse-free survival for 3 years and secondary endpoints are safety, including the incidence of adverse events, and grading of neuropathy with each treatment cycle. The planned sample size of 75 patients is appropriate for this trial. The data will be analyzed on an intention-to-treat basis, assuming a two-sided test with a 5% level of significance. DISCUSSION: In contrast to previous trials, the current study involves administration of S-1 until one year after surgery in addition to prior S-1 plus oxaliplatin, and is the first study to evaluate the safety and efficacy of S-1 plus oxaliplatin followed by S-1 for up to one year in patients with curatively resected stage III gastric cancer. TRIAL REGISTRATION: This trial is registered in the University Hospital Medical Information Network’s Clinical Trials Registry (UMIN-CTR) registration number, R000029656  (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029656). Registered January 24, 2017. BioMed Central 2018-02-13 /pmc/articles/PMC5812232/ /pubmed/29439671 http://dx.doi.org/10.1186/s12885-018-4109-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Study Protocol
Namikawa, Tsutomu
Maeda, Hiromichi
Kitagawa, Hiroyuki
Oba, Koji
Tsuji, Akihito
Yoshikawa, Takaki
Kobayashi, Michiya
Hanazaki, Kazuhiro
Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title_full Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title_fullStr Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title_full_unstemmed Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title_short Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol
title_sort treatment using oxaliplatin and s-1 adjuvant chemotherapy for pathological stage iii gastric cancer: a multicenter phase ii study (tosa trial) protocol
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812232/
https://www.ncbi.nlm.nih.gov/pubmed/29439671
http://dx.doi.org/10.1186/s12885-018-4109-z
work_keys_str_mv AT namikawatsutomu treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT maedahiromichi treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT kitagawahiroyuki treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT obakoji treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT tsujiakihito treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT yoshikawatakaki treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT kobayashimichiya treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol
AT hanazakikazuhiro treatmentusingoxaliplatinands1adjuvantchemotherapyforpathologicalstageiiigastriccanceramulticenterphaseiistudytosatrialprotocol